SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  For example, here is how to disable FireFox ad content blocking while on Silicon Investor.

   Biotech / MedicalBICO & VITK


Previous 10 Next 10 
To: Terry D. who wrote (2372)7/7/1999 3:53:00 AM
From: HungryMan
   of 2395
 
Damn this thread is D-E-A-D!! :) WAKE UP people! We need some good news for this to move.. MM's are killing us, IMO. Good luck..

-- Hungry

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: HungryMan who wrote (2373)7/7/1999 8:48:00 AM
From: Ron Iozzio
   of 2395
 
Everyone is on the RB thread

Have a good day

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: Ron Iozzio who wrote (2374)7/7/1999 1:27:00 PM
From: HungryMan
   of 2395
 
RB???

-- Hungry

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: HungryMan who wrote (2375)7/7/1999 1:32:00 PM
From: Bryan
   of 2395
 
RB = Raging Bull
ragingbull.com

Happy reading !


Share RecommendKeepReplyMark as Last Read


To: David Dickter who wrote ()8/24/1999 5:55:00 PM
From: Ellis Rudman
   of 2395
 
What's going on today??? 49 million shares traded in a range from 11 to 18 cents??? something smells more rotten than usual.

Ellis Rudman

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: Ellis Rudman who wrote (2377)1/3/2000 9:34:00 PM
From: afrayem onigwecher
   of 2395
 
What's going on today??? +41.2% 21 million shares traded in a range from 5 to 7.3 cents??? something smells more than usual.

BICO : BIOCONTROL TECHNOLOGY INC (OTC:BB) 9:28 PM EST
Last Trade 0.072 Open 0.052 EPS Growth Rate N/A
Change +0.021 Previous Close 0.051 EPS (TTM) -0.06
% Change +41.2% Today's High 0.073 P/E 0.00
Last Trade 4:00 PM Today's Low 0.051 Market Cap 63.72 Mil
Bid 0.072 52 Wk High 0.531 Shares Outstanding 884.97 Mil
Ask 0.073 52 Wk Low 0.016 Dividend 0.00
Volume 21,554,400 Avg Daily Vol 9,607,900 Yield 0.00

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: David Dickter who wrote ()1/12/2000 11:44:00 AM
From: Richard Hoenes
   of 2395
 
01/12 08:17 Biocontrol Subsidiary, IDT, Receives FDA Marketing Clearance For
<BICO.OB>

Biocontrol Subsidiary, IDT, Receives FDA Marketing Clearance
For ThermoChem-HT System(TM)

PITTSBURGH, Jan. 12 /PRNewswire/ -- Biocontrol Technology, Inc. (OTC Bulletin Board: BICO) subsidiary, IDT, Inc., in conjunction with HemoCleanse, Inc., announced today that they have received FDA clearance to market the ThermoChem-HT System(TM) and related disposables.

The ThermoChem-HT System and disposables will now be available to hospitals and doctors nationwide to help standardize a revolutionary cancer treatment. This treatment has been developed clinically at Wake Forest University Baptist Medical Center since 1991 by Dr. Brian Loggie, a surgical oncologist, with correlative laboratory studies performed by Ronald Fleming, Pharm. D., an adjunct professor. It now is offered at the Medical Center as standard-of-care for the treatment of ovarian, gastrointestinal, and other tumors that have spread to the lining surface (peritoneum) of the abdomen and pelvis (peritoneal carcinomatosis, peritoneal mesothelioma, pseudomyxoma peritoneum).

"We are very pleased with the clinical results that have been achieved using the combination of surgery, Intraperitoneal Hyperthermia, and chemotherapy," said Dr. Loggie.

The intended use of the ThermoChem-HT System is to raise the core temperature of the peritoneum to the desired targeted temperature in the 41 degree Celsius (105.8 degrees Fahrenheit) to 42 degrees Celsius (107.6 degrees Fahrenheit) range by continuously lavaging the peritoneum with circulating sterile solution. Heating of the peritoneum can make the area more receptive to adjunct therapies physicians might choose, such as chemotherapy or natural biological agents.

Glenn Keeling, CEO of IDT, stated, "The FDA clearance is a significant step. It reinforces our belief that by standardizing the IPH with the ThermoChem-HT System, this cancer treatment will be available to more patients." IDT is pursuing a strategic partnership as part of its overall marketing plan and continues to develop additional cancer treatment protocols to be submitted to the FDA.

In addition, IDT is in the process of submitting clinical and technical data to a European Notified Body. This process will lead to the awarding of the CE Mark, which signifies that the device meets the requirements for distribution into the European community.

In an agreement with IDT, Biocontrol Technology, Inc., which is an FDA approved manufacturer and an ISO 9000 manufacturing facility, is manufacturing the ThermoChem-HT System at its Indiana, PA facility.

Biocontrol Technology has its corporate offices in Pittsburgh, PA and is involved in the development and manufacture of biomedical devices and environmental products. IDT, Inc., a subsidiary of Biocontrol also located in Pittsburgh, PA, holds exclusive worldwide marketing rights to the ThermoChem- HT System and related disposables for regional hyperthermia and the ThermoChem System and related disposables for whole body hyperthermia.

Website: www.bico.com.

Investor Relations Newsline Number: 1-800-357-6204.

This press release contains statements of a forward looking nature. Shareholders and potential investors are cautioned that such statements are predictions and actual events or results may vary significantly. SOURCE Biocontrol Technology, Inc.

-0- 01/12/2000

/CONTACT: Investors, Diane McQuaide, 412-429-0673, or fax, 412-279-9690, or Media, Susan Taylor, 412-429-0673, or fax, 412-279-5041, both of Biocontrol Technology/

/Web site: bico.com / -- PHW011 -- 9874 01/12/2000 08:01 EST prnewswire.com Copyright PR Newswire 1998. All rights reserved.

Share RecommendKeepReplyMark as Last Read


To: David Dickter who wrote ()2/8/2000 7:15:00 PM
From: Michael Page
   of 2395
 
All Hype?

Check these guys out: mightymicrocap

The post your picks and have a daily hot list email newsletter. They are going to have comic book characters giving editorials!

You can't believe this!

Share RecommendKeepReplyMark as Last Read


To: afrayem onigwecher who wrote (2378)2/10/2000 6:35:00 PM
From: John Nasser
   of 2395
 
bid price .45 after hours.... someone knows something.

Share RecommendKeepReplyMark as Last Read


To: David Dickter who wrote ()2/17/2000 1:47:00 PM
From: david sandel
   of 2395
 
Thursday February 17, 12:44 pm Eastern Time

Company Press Release

SOURCE: Biocontrol Technology, Inc.

Biocontrol Technology, Inc. Subsidiary,
IDT, Receives FDA Approval to
Continue Lung Cancer Study at the University of Texas
Medical Branch at Galveston

PITTSBURGH, Feb. 17 /PRNewswire/ -- Biocontrol Technology, Inc. (OTC Bulletin Board:
BICO - news) announced today that its subsidiary, IDT, Inc., in conjunction with HemoCleanse, Inc.
located in Lafayette, Indiana, has received FDA approval and Institutional Review Approval from
the University of Texas Medical Branch at Galveston to continue a human clinical trial to treat
patients with non-small cell lung cancer (NSCLC).

The clinical trial will utilize the ThermoChem technology and disposables to deliver
Perfusion-Induced Systemic Hyperthermia (PISH), a therapy in which core body temperature is
raised to 42 degrees C (107.6 degrees F) for two hours by direct extracorporeal (outside of the
body) heating of the blood. Non-small cell lung cancer is a combination of at least three malignant
cell structures found in the tissues of the lungs. Lung cancer remains a major cause of cancer
morbidity and mortality in the United States.

IDT completed the first phase of the FDA approved study, which involved five patients in July 1998.
That phase of the study involved patients with Stage IV non-small cell lung cancer where cancer had
spread to other parts of the body. Results of that study are pending publication.

In this most recent approval, the FDA allowed Stage IIIb patients to be included. Stage IIIb is
usually non-operative cancer that has spread to the chest wall or diaphragm near the lung or cancer
that has spread to the lymph nodes in the area that separates the two lungs or to the lymph nodes on
the other side of the chest or in the neck.

The objective of the clinical trial is to evaluate the ThermoChem technology as a delivery system for
Perfusion-Induced Systemic Hyperthermia in the treatment of non-small cell lung cancer with regard
to patient selection, tumor response, patient performance status, and patient survival.

In Perfusion-Induced Systemic Hyperthermia, the ThermoChem technology is composed of the
ThermoChem-HT System(TM) and ThermoChem-SB System(TM). The ThermoChem-HT System
heats and circulates the blood while maintaining core body temperature, and ThermoChem-SB
System balances blood chemistries on a ``real-time' basis and removes toxins from the blood. The
Company believes this interface between two systems is essential to safely deliver Perfusion-Induced
Systemic Hyperthermia.

IDT has been developing the ThermoChem technology as a safe delivery system for whole body and
regional hyperthermia since 1992. The FDA recently cleared the ThermoChem-HT System for
marketing where the intended use is to raise the core temperature of the peritoneum to 42 degrees C
(107.6 degrees F) by continuously lavaging (bathing) the peritoneum with sterile solution.
Intraperitoneal hyperthermia is part of an operative procedure used to treat patients with advanced
ovarian and gastrointestinal cancer.

Biocontrol Technology has its corporate offices in Pittsburgh, PA, and is involved in the development
and manufacture of biomedical devices and environmental products. IDT, Inc., a subsidiary of
Biocontrol also located in Pittsburgh, PA, holds exclusive worldwide marketing rights to the
ThermoChem-HT technology and related disposables for regional hyperthermia and the
ThermoChem technology and related disposables for whole body hyperthermia.

This press release contains statements of a forward-looking nature. Shareholders and potential
investors are cautioned that such statements are predictions and actual events or results may vary
significantly.

WEBSITE: www.bico.com
INVESTOR RELATIONS NEWSLINE NUMBER: 1-800-357-6204

SOURCE: Biocontrol Technology, Inc.

More Quotes and News:
Biocontrol Technology Inc (OTC BB:BICO.OB - news)
Related News Categories: biotech, medical/pharmaceutical

Help

Copyright ¸ 2000 Yahoo! All Rights Reserved. Privacy Policy - Terms of Service
Copyright 2000 PRNewswire. All rights reserved. Republication or redistribution of PRNewswire content is
expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any
errors or delays in the content, or for any actions taken in reliance thereon.

Share RecommendKeepReplyMark as Last ReadRead Replies (1)
Previous 10 Next 10